Tildrakizumab

https://clinicaltrials.gov/ct2/show/NCT03897088?type=Intr&cond=Psoriasis&lupd_s=03%2F18%2F2019&lupd_d=14

Condition :   Scalp Psoriasis

Interventions :   Drug: Tildrakizumab;   Drug: Placebo

Sponsor :   Sun Pharma Global FZE

Not yet recruiting

Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasi

NCT03897088

Mon, 01 Apr 2019 12:00:00 EDT

Last Update Posted: 04/01/19 08:48AM

https://clinicaltrials.gov/ct2/show/NCT01729754?type=Intr&cond=Psoriasis&lupd_s=03%2F12%2F2019&lupd_d=14

Condition :   Plaque Psoriasis

Interventions :   Drug: Tildrakizumab 200 mg;   Drug: Tildrakizumab 100 mg;   Drug: Tildrakizumab Placebo;   Drug: Etanercept Placebo;   Drug: Etanercept 50 mg

Sponsor :   Sun Pharma Global FZE

Active, not recruiting

A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)

NCT01729754

Tue, 20 Nov 2012 12:00:00 EST

Last Update Posted: 03/26/19 09:35AM